{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/A4001080","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00782301","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Randomized Controlled Trial","arm_groups":[{"arm_group_label":"Maraviroc","arm_group_description":"","arm_type":"Active Comparator"},{"arm_group_label":"Etravirine","arm_group_description":"","arm_type":"Active Comparator"}],"assignment":"Parallel","brief_summary":"Confirm the safety of maraviroc when used as a component of combination antiretroviral therapy in HIV and Hepatitis co-infected patients.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients","conditions":[{"DisplayValue":"Hepatitis B","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_B","LookupValue":"Hepatitis B","LookupValue_OneLinkTx":""},{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Human Immunodeficiency Virus","LookupValue_OneLinkTx":""},{"DisplayValue":"Hepatitis C","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_C","LookupValue":"Hepatitis C, Chronic","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:57:35","criteria":"Inclusion Criteria: HIV-1 RNA viral load of ≥1000 copies/mL at the screening visit. Detectable HCV RNA levels or Hepatitis B surface antigen (HBsAg) positive. Previous antiretroviral treatment experience with at least 2 antiretroviral drug classes for ≥3 months. Documented resistance to an NNRTI as well as documented resistance to another antiretroviral agent. CCR5 tropic virus detected by the TrofileTM assay. Exclusion Criteria: Suspected or documented active, untreated HIV-1 related Opportunistic Infection (OI) or other condition requiring acute therapy at the time of randomization (subjects on a stable (>1 month) secondary OI prophylaxis regimen are eligible for the study; subjects on a primary OI prophylaxis regimen of any duration are also eligible for the study). Prior treatment with darunavir/ritonavir, raltegravir, or another integrase inhibitor, etravirine, maraviroc or another CCR5 inhibitor for more than 14 days at any time. Subjects receiving treatment for chronic Hepatitis or the expected need to initiate HCV treatment within 48 weeks of randomization. (Subjects who were previously treated for Hepatitis C are eligible for the study). AST and/or ALT greater than 5 times the upper limit of normal (ACTG Grade 3).","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 4","display_phase_internal":"PHASE_4","display_status":"Withdrawn","display_status_internal":"RECSTATUS_I_WITHDRAWN","endpoint":"","enrollment":"0","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"d81c2bb0-2d82-5041-b832-594f1fd63004","internal":{"content":null,"contentDigest":"8c076c8858f1f8defb8f0e491afd1595","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: HIV-1 RNA viral load of ≥1000 copies/mL at the screening visit. Detectable HCV RNA levels or Hepatitis B surface antigen (HBsAg) positive. Previous antiretroviral treatment experience with at least 2 antiretroviral drug classes for ≥3 months. Documented resistance to an NNRTI as well as documented resistance to another antiretroviral agent. CCR5 tropic virus detected by the TrofileTM assay. Exclusion Criteria: Suspected or documented active, untreated HIV-1 related Opportunistic Infection (OI) or other condition requiring acute therapy at the time of randomization (subjects on a stable (>1 month) secondary OI prophylaxis regimen are eligible for the study; subjects on a primary OI prophylaxis regimen of any duration are also eligible for the study). Prior treatment with darunavir/ritonavir, raltegravir, or another integrase inhibitor, etravirine, maraviroc or another CCR5 inhibitor for more than 14 days at any time. Subjects receiving treatment for chronic Hepatitis or the expected need to initiate HCV treatment within 48 weeks of randomization. (Subjects who were previously treated for Hepatitis C are eligible for the study). AST and/or ALT greater than 5 times the upper limit of normal (ACTG Grade 3).","interventions":[{"arm_group_label":"Maraviroc","intervention_description":"maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.","intervention_name":"maraviroc","intervention_type":"Drug"},{"arm_group_label":"Etravirine","intervention_description":"etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.","intervention_name":"etravirine","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["HIV and Hepatitis co-infection"],"last_follow_up_date":"02/01/2010 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001080&StudyName=Maraviroc%20Versus%20Etravirine%20In%20Combination%20With%20Antiretroviral%20Therapy%20In%20Drug%20Experienced%20HIV%20And%20Hepatitis%20Co-Infected%20Patients"}],"locations":[{"City":"Bellaire","Latitude":"29.7057858","CountryDisplay":"United States","Longitude":"-95.4588299","Name":"Pfizer Investigational Site","StateDisplay":"TX","PostalCode":"77401","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Worcester","Latitude":"42.2717443","CountryDisplay":"United States","Longitude":"-71.7588217","Name":"Pfizer Investigational Site","StateDisplay":"MA","PostalCode":"01655","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Dallas","Latitude":"32.8113367","CountryDisplay":"United States","Longitude":"-96.8397899","Name":"Pfizer Investigational Site","StateDisplay":"TX","PostalCode":"75390","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Atlanta","Latitude":"33.7717008","CountryDisplay":"United States","Longitude":"-84.3726049","Name":"Pfizer Investigational Site","StateDisplay":"GA","PostalCode":"30308","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Toronto","Latitude":"43.6584136","CountryDisplay":"Canada","Longitude":"-79.3891419","Name":"Pfizer Investigational Site","StateDisplay":"ON","PostalCode":"M5G 2N2","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Bydgoszcz","Latitude":"53.1224661","CountryDisplay":"Poland","Longitude":"18.0102643","Name":"Pfizer Investigational Site","StateDisplay":null,"PostalCode":"85-030","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Stafford","Latitude":"29.6160671","CountryDisplay":"United States","Longitude":"-95.5577221","Name":"Pfizer Investigational Site","StateDisplay":"TX","PostalCode":"77477","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Wilton Manors","Latitude":"26.1603626","CountryDisplay":"United States","Longitude":"-80.138934","Name":"Pfizer Investigational Site","StateDisplay":"FL","PostalCode":"33305","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"New Orleans","Latitude":"29.9595769","CountryDisplay":"United States","Longitude":"-90.0770127","Name":"Pfizer Investigational Site","StateDisplay":"LA","PostalCode":"70112","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Atlanta","Latitude":"33.7440941","CountryDisplay":"United States","Longitude":"-84.377861","Name":"Pfizer Investigational Site","StateDisplay":"GA","PostalCode":"30312","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Clearwater","Latitude":"27.9765043","CountryDisplay":"United States","Longitude":"-82.7428057","Name":"Pfizer Investigational Site","StateDisplay":"FL","PostalCode":"33765","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vancouver","Latitude":"49.278915","CountryDisplay":"Canada","Longitude":"-123.12909","Name":"Pfizer Investigational Site","StateDisplay":"BC","PostalCode":"V6Z 2C7","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Orlando","Latitude":"28.5542151","CountryDisplay":"United States","Longitude":"-81.3454417","Name":"Pfizer Investigational Site","StateDisplay":"FL","PostalCode":"32803","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Mt. Vernon","Latitude":"40.9087956","CountryDisplay":"United States","Longitude":"-73.8330844","Name":"Pfizer Investigational Site","StateDisplay":"NY","PostalCode":"10550","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Worcester","Latitude":"42.279853","CountryDisplay":"United States","Longitude":"-71.7919027","Name":"Pfizer Investigational Site","StateDisplay":"MA","PostalCode":"01605","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Conroe","Latitude":"30.3120301","CountryDisplay":"United States","Longitude":"-95.4253757","Name":"Pfizer Investigational Site","StateDisplay":"TX","PostalCode":"77301","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Tulsa","Latitude":"36.1005816","CountryDisplay":"United States","Longitude":"-95.9251211","Name":"Pfizer Investigational Site","StateDisplay":"OK","PostalCode":"74135","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Safety Harbor","Latitude":"28.0055309","CountryDisplay":"United States","Longitude":"-82.6861446","Name":"Pfizer Investigational Site","StateDisplay":"FL","PostalCode":"34695","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"}],"masking":"Open","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"16","minimum_age_raw":"16 Years","modified_date":"10/01/2018 22:55:01","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Multicenter, Randomized, Open, Comparative Trial Of Maraviroc Versus Etravirine Each In Combination With Darunavir/Ritonavir And Raltegravir For The Treatment Of Antiretroviral-Experienced HIV-1 Subjects Co-Infected With Hepatitis C And/Or Hepatitis B","org_study_id":"A4001080","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Withdrawn - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"PHASE 4","primary_compl_date":"02/01/2010 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Percentage of subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L through Week 48.","outcome_time_frame":"48 weeks","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Percentage of HCV treated subjects with Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L through 96.","outcome_time_frame":"48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Time to development of Grade 3 and Grade 4 ALT test abnormalities associated with a change from baseline ALT ≥100 IU/L.","outcome_time_frame":"96 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of subjects with Hy’s law abnormalities through Week 48.","outcome_time_frame":"48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of HCV treated subjects with Hy’s law abnormalities through Week 96.","outcome_time_frame":"96 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in mean Hepatitis C viral load through Week 48","outcome_time_frame":"48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Undetectable HCV viral load 24 weeks after stopping HCV treatment.","outcome_time_frame":"240 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Percentage of subjects with HIV-1 RNA levels <48 copies/mL at Week 48.","outcome_time_frame":"48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in CD4+ cell count at Week 48.","outcome_time_frame":"48 weeks","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Change from baseline in mean hepatitis B DNA through Week 48","outcome_time_frame":"48 Weeks","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"Viiv Healthcare","collaborators":["Pfizer"]},"start_date":"03/01/2009 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001080"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}